| Cell line name |
LoVo-MEK-R |
|---|
| Accession |
CVCL_V402 |
|---|
| Resource Identification Initiative |
To cite this cell line use: LoVo-MEK-R (RRID:CVCL_V402) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_88249; 391210-10-9 (PD0325901).
Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Colon adenocarcinoma (NCIt: C4349) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0399 (LoVo) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
56Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=22402123; DOI=10.1158/1535-7163.MCT-11-1010
Hatzivassiliou G., Liu B., O'Brien C., Spoerke J.M., Hoeflich K.P., Haverty P.M., Soriano R.H., Forrest W.F., Heldens S., Chen H.-F., Toy K., Ha C., Zhou W., Song K., Friedman L.S., Amler L.C., Hampton G.M., Moffat J., Belvin M.P., Lackner M.R.
ERK inhibition overcomes acquired resistance to MEK inhibitors.
Mol. Cancer Ther. 11:1143-1154(2012) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_V402
|
|---|
| Encyclopedic resources |
Wikidata; Q54902903
|
|---|
| Polymorphism and mutation databases |
Cosmic; 1927245
|
|---|
| Entry history |
|---|
| Entry creation | 16-Apr-2014 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 18 |
|---|
